Top Medical News
Jairia Dela Cruz, 2 days ago
For people undergoing chemotherapy, tuning in to some music may help soothe nausea symptoms, as reported in a small pilot study.
4 days ago
Children born to mothers who used acetaminophen during pregnancy do not appear to have poor cognitive development at 4 years of age, as shown in a study.
21 Mar 2023
Patients with human T-lymphotropic virus 1 (HTLV-1) infection may develop erectile dysfunction (ED), and time to progression to its severe form is significantly associated with the degree of neurologic compromise at baseline, reveals a study.
Stephen Padilla, 21 Mar 2023
Healthcare providers and other care partners need greater awareness and training on neurocognitive impairment, mental health, and comorbidities that afflict older people living with HIV (PLHIV), suggests a Singapore study.
16 Mar 2023
For individuals with epilepsy, listening to classical music, specifically Mozart’s sonata, does not appear to provide any form of relief, according to the results of a meta-analysis.
16 Mar 2023
New drug applications approved by US FDA as of 01-15 March 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
15 Mar 2023
Individuals who have trouble falling asleep and who use sleep medications are at increased risk of dementia, as reported in a study.
04 May 2018
Multiple sclerosis (MS) is one of the most common neurological disorders – affecting over 2.3 million people globally – and it is the leading cause of nontraumatic disability in young adults. However,the availability of supportive resources and services for people with MS is scarce in many regions of the world. In Malaysia, the prevalence of MS is estimated at 2-3/100,000; the current Malaysian clinical practice guidelines on the management of MS recommend disease modifying agents, such as interferon-β and teriflunomide, as first-line therapeutic agents. In this article, Dr Singer - in partnership with Sanofi and the Malaysian Society of Neurosciences - shares his insights into managing MS dynamically, highlighting the importance of early intervention in improving patient outcomes.
Audrey Abella, 28 Feb 2023
In the ARAMIS* trial, dual antiplatelet therapy (DAPT) using clopidogrel and aspirin was noninferior to intravenous thrombolysis (IVT) using alteplase in Chinese patients with minor nondisabling ischaemic stroke presenting within 4.5 hours of symptom onset.
Elvira Manzano, 27 Feb 2023
The combination of cilostazol and isosorbide mononitrate boosts functional and cognitive outcomes in patients who have had lacunar strokes (subcortical infarcts <20 mm in diameter) in the phase II LACI-2* trial.
Audrey Abella, 24 Feb 2023
Findings from the RESCUE BT2 study support the potential of tirofiban to improve neurologic outcomes than aspirin in patients with acute ischaemic stroke without visible large or medium vessel occlusion (LVO or MVO) within 24 hours of last known well or of onset of stroke symptom progression. However, its efficacy was countered by the higher rate of symptomatic intracranial haemorrhage (sICH).
Jairia Dela Cruz, 24 Feb 2023
Not a lot of individuals, especially women, are initiated on dual antiplatelet therapy (DAPT) with aspirin and clopidogrel after a transient ischaemic attack or minor acute ischaemic stroke, and this is despite evidence showing that such a strategy may prevent a second and potentially more serious stroke, as reported in a study presented at ISC 2023.
Jairia Dela Cruz, 22 Feb 2023
Butylphthalide, a novel medication that contains a compound found in celery, appears to help with functional recovery in patients with ischaemic stroke, as shown in a study presented at ISC 2023.
Elaine Soliven, 19 Feb 2023
Among Chinese patients with acute ischaemic stroke, intravenous (IV) tenecteplase is noninferior to the standard-of-care alteplase in achieving an excellent functional outcome, with a similar safety profile, when given within 4.5 hours of symptom onset, according to the TRACE-2* trial presented at ISC 2023.
Roshini Claire Anthony, 26 Dec 2022
The endothelin-B receptor agonist sovateltide appears to improve neurological outcomes in patients with acute cerebral ischaemic stroke (ACIS), according to a phase III trial presented at WSC 2022.